JYResearcher profile · from public sources
Jun Yu
Now
Trials, publications and grants since Nov 2024.
Publication
Albumin-bound paclitaxel-induced stromal reprogramming drives resistance to neoadjuvant chemotherapy in patients with pancreatic cancer.
Science translational medicine, Nov 2026
Publication
Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 trial.
Signal transduction and targeted therapy, Nov 2026
Publication
Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic-Epigenetic Rewiring.
Cancer discovery, Aug 2026
Publication
Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancreatic cancer.
Signal transduction and targeted therapy, Apr 2026
Publication
Rationally and in silico guided APOBEC3F-directed CBE for enhanced PDAC genetic therapy.
Communications biology, Mar 2026
Publication
An Insulin-Exosome-TNFAIP8 Axis Drives Stromal Fibrosis and Therapeutic Resistance in Pancreatic Cancer.
Advanced science (Weinheim, Baden-Wurttemberg, Germany), Feb 2026
Publication
Pathomics Signature for Prognosis and CA19-9 Interception in Pancreatic Ductal Adenocarcinoma: A Real-Life, Multi-Center Study.
Advanced science (Weinheim, Baden-Wurttemberg, Germany), Jan 2026
Publication
Targeting of the m6A eraser ALKBH5 suppresses stemness and chemoresistance of colorectal cancer.
Nature communications, Dec 2025
Publication
Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pancreatic cancer.
Nature communications, Dec 2025
Co-authors
Who links you
Enter another researcher's profile link or ID to see who has published with both of you.
You have published with Wei Kang directly.
Is this you? Request a correction or removal: support@frontlightresearch.com
Report an error